Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Clinical trial NCT05283330 · RECRUITING

Trial details

NCT number: NCT05283330
Sponsor: Orano Med Theranostics, SAS
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Cervical Cancer Breast Cancer Colon Cancer NSCLC mCRPC (Metastatic Castration-resistant Prostate Cancer)Glioblastoma Nonsmall Cell Lung Cancer

Start date: 2022-12-22
Primary completion: 2027-01-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.